NCCN guidelines also recognize that the use of cell free DNA (cfDNA) testing can detect some FGFR2 fusion breakpoints in cholangiocarcinoma, but the sensitivity is lower than that of tumor tissue testing [77]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.